Depression and Anxiety Prevalence in People with Cystic Fibrosis and Their Caregivers: a Systematic Review and Meta-analysis
Overview
Affiliations
Background: Prevalence of depression and anxiety in people with cystic fibrosis (PwCF) and their caregivers is high, however, results have been inconsistent. This systematic review and meta-analysis aimed to estimate the prevalence of depression and anxiety in PwCF and their caregivers and explore sources of heterogeneity.
Method: MEDLINE, EMBASE, CINAHL plus and PsychINFO databases were searched from inception to January 2021. Studies were included if a specific psychometric tool (PT) to assess depression or anxiety (rather than quality of life) was used and did not involve a transitory patient state. Random-effects models were applied due to high anticipated heterogeneity and Iestimates were calculated. Sources of heterogeneity were explored through subgroup comparisons. The presence of small-study effects was investigated visually using funnel plots and statistically using the Egger test.
Results: A total of 94 articles (48 full-text publications, 46 abstracts) were included. Depression prevalence in adolescents aged 12-18 years (n = 2386), adults (n = 9206) and caregivers (n = 6617) were 18.7% (95% CI 12.8-25.3%, I = 89.2%), 27.2% (95% CI 23.6-31%, I = 90.4%), and 32.8% (95% CI 27.9-37.9%, I = 90.3%), respectively. Anxiety prevalence in adolescents aged 12-18 years (n = 2142) was 26% (95% CI 19.6-33%, I = 86.4%), 28.4% (95% CI 25-31.9%, I = 85%) for adults (n = 8175), and 38.4% (95% CI 30.8-46.2%, I = 94.6%) for caregivers (n = 5931). Prevalence differed by the PT used and study location.
Discussion: This comprehensive analysis found the prevalence of depression and anxiety in PwCF and their caregivers to be high, supporting recommendations for regular screening. Choice of PT significantly influenced prevalence, indicating a need for future studies to identify the optimal PT for each CF population to identify those most at risk.
Sutering T, Bode S, Fischer R, Fabricius D Adv Respir Med. 2024; 92(6):559-572.
PMID: 39727500 PMC: 11672886. DOI: 10.3390/arm92060049.
Magee D, Kicker S, Thomas A J Am Med Inform Assoc. 2024; 32(3):579-585.
PMID: 39715481 PMC: 11833481. DOI: 10.1093/jamia/ocae241.
Edinburgh postnatal depression scale score elevation in caregivers of infants with cystic fibrosis.
Gillespie M, Jayaram S, Eisner M, Sliemers S, Pasley K, McCoy K Pediatr Pulmonol. 2024; 60(1):e27364.
PMID: 39469979 PMC: 11740653. DOI: 10.1002/ppul.27364.
Amygdalar involvement in respiratory dysfunction.
Trevizan-Bau P, Hayes J, Bolser D, Reznikov L Front Physiol. 2024; 15:1424889.
PMID: 39263625 PMC: 11387172. DOI: 10.3389/fphys.2024.1424889.
Racial inequities and rare variants: Impact on cystic fibrosis diagnosis and treatment.
Wu M, Davis J, Zhao C, Daley T, Oliver K J Clin Transl Endocrinol. 2024; 36:100344.
PMID: 38765466 PMC: 11099334. DOI: 10.1016/j.jcte.2024.100344.